Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France. more
Time Frame | IPHA | Sector | S&P500 |
---|---|---|---|
1-Week Return | 27.81% | -2.06% | -0.55% |
1-Month Return | 41.18% | -1.92% | 2.72% |
3-Month Return | -4% | -10.4% | 7.66% |
6-Month Return | 6.93% | -4.6% | 10.15% |
1-Year Return | -11.84% | 4.06% | 27.53% |
3-Year Return | -56.97% | 1.94% | 32.31% |
5-Year Return | -65.11% | 36.48% | 89.2% |
10-Year Return | -64.3% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 68.97M | 56.83M | 12.11M | 49.64M | 51.90M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":82.4,"profit":true},{"date":"2021-12-31","value":17.56,"profit":true},{"date":"2022-12-31","value":71.97,"profit":true},{"date":"2023-12-31","value":75.25,"profit":true}] |
Cost of Revenue | 45.16M | 3.04M | 47.00M | 51.66M | 56.02M | [{"date":"2019-12-31","value":80.61,"profit":true},{"date":"2020-12-31","value":5.43,"profit":true},{"date":"2021-12-31","value":83.9,"profit":true},{"date":"2022-12-31","value":92.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 23.82M | 53.79M | (34.89M) | (2.02M) | (4.12M) | [{"date":"2019-12-31","value":44.27,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-64.87,"profit":false},{"date":"2022-12-31","value":-3.76,"profit":false},{"date":"2023-12-31","value":-7.66,"profit":false}] |
Gross Margin | 34.53% | 94.65% | (288.08%) | (4.08%) | (7.94%) | [{"date":"2019-12-31","value":36.48,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-304.37,"profit":false},{"date":"2022-12-31","value":-4.31,"profit":false},{"date":"2023-12-31","value":-8.39,"profit":false}] |
Operating Expenses | 50.87M | 75.38M | 59.94M | 66.06M | 64.57M | [{"date":"2019-12-31","value":67.48,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":79.51,"profit":true},{"date":"2022-12-31","value":87.64,"profit":true},{"date":"2023-12-31","value":85.66,"profit":true}] |
Operating Income | (27.05M) | (13.69M) | (47.83M) | (11.65M) | (12.67M) | [{"date":"2019-12-31","value":-2705300000,"profit":false},{"date":"2020-12-31","value":-1369200000,"profit":false},{"date":"2021-12-31","value":-4782500000,"profit":false},{"date":"2022-12-31","value":-1165100000,"profit":false},{"date":"2023-12-31","value":-1266900000,"profit":false}] |
Total Non-Operating Income/Expense | 7.73M | (17.43M) | 4.69M | (1.09M) | 7.64M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-225.62,"profit":false},{"date":"2021-12-31","value":60.75,"profit":true},{"date":"2022-12-31","value":-14.15,"profit":false},{"date":"2023-12-31","value":98.82,"profit":true}] |
Pre-Tax Income | (20.76M) | (63.98M) | (45.48M) | (57.97M) | (7.57M) | [{"date":"2019-12-31","value":-2075900000,"profit":false},{"date":"2020-12-31","value":-6398400000,"profit":false},{"date":"2021-12-31","value":-4547800000,"profit":false},{"date":"2022-12-31","value":-5797200000,"profit":false},{"date":"2023-12-31","value":-757000000,"profit":false}] |
Income Taxes | 206.00K | 6.76M | 13.66M | 41.13M | (9.73M) | [{"date":"2019-12-31","value":0.5,"profit":true},{"date":"2020-12-31","value":16.44,"profit":true},{"date":"2021-12-31","value":33.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-23.65,"profit":false}] |
Income After Taxes | (20.96M) | (70.75M) | (59.14M) | (99.10M) | 2.16M | [{"date":"2019-12-31","value":-971.05,"profit":false},{"date":"2020-12-31","value":-3276.84,"profit":false},{"date":"2021-12-31","value":-2739.05,"profit":false},{"date":"2022-12-31","value":-4590.23,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (20.76M) | (63.98M) | (45.48M) | (57.97M) | (7.57M) | [{"date":"2019-12-31","value":-2075900000,"profit":false},{"date":"2020-12-31","value":-6398400000,"profit":false},{"date":"2021-12-31","value":-4547800000,"profit":false},{"date":"2022-12-31","value":-5797200000,"profit":false},{"date":"2023-12-31","value":-757000000,"profit":false}] |
Income From Discontinued Operations | (7.33M) | (7.33M) | (7.33M) | (131.00K) | - | [{"date":"2019-12-31","value":-733100000,"profit":false},{"date":"2020-12-31","value":-733100000,"profit":false},{"date":"2021-12-31","value":-733100000,"profit":false},{"date":"2022-12-31","value":-13100000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (20.96M) | (70.75M) | (59.14M) | (99.10M) | (7.57M) | [{"date":"2019-12-31","value":-2096500000,"profit":false},{"date":"2020-12-31","value":-7074700000,"profit":false},{"date":"2021-12-31","value":-5913600000,"profit":false},{"date":"2022-12-31","value":-9910300000,"profit":false},{"date":"2023-12-31","value":-757000000,"profit":false}] |
EPS (Diluted) | (0.14) | (0.43) | (0.84) | - | 0.02 | [{"date":"2019-12-31","value":-724,"profit":false},{"date":"2020-12-31","value":-2134,"profit":false},{"date":"2021-12-31","value":-4190,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
IPHA | |
---|---|
Cash Ratio | 2.40 |
Current Ratio | 2.92 |
Quick Ratio | 2.84 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IPHA | |
---|---|
ROA (LTM) | -13.76% |
ROE (LTM) | -78.59% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IPHA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.81 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.19 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IPHA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.29 |
P/B | 5.89 |
Price/FCF | 130 |
EV/R | 4.55 |
EV/Ebitda | NM |
Innate Pharma (IPHA) share price today is $2.16
Yes, Indians can buy shares of Innate Pharma (IPHA) on Vested. To buy Innate Pharma from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IPHA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Innate Pharma (IPHA) via the Vested app. You can start investing in Innate Pharma (IPHA) with a minimum investment of $1.
You can invest in shares of Innate Pharma (IPHA) via Vested in three simple steps:
The 52-week high price of Innate Pharma (IPHA) is $3.51. The 52-week low price of Innate Pharma (IPHA) is $1.29.
The price-to-earnings (P/E) ratio of Innate Pharma (IPHA) is
The price-to-book (P/B) ratio of Innate Pharma (IPHA) is 5.89
The dividend yield of Innate Pharma (IPHA) is 0.00%
The market capitalization of Innate Pharma (IPHA) is $186.18M
The stock symbol (or ticker) of Innate Pharma is IPHA